Literature DB >> 17059688

Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.

Bharathi Laxman1, Scott A Tomlins, Rohit Mehra, David S Morris, Lei Wang, Beth E Helgeson, Rajal B Shah, Mark A Rubin, John T Wei, Arul M Chinnaiyan.   

Abstract

We recently reported the identification of recurrent gene fusions in the majority of prostate cancers involving the 5' untranslated region of the androgen-regulated gene TMPRSS2 and the ETS family members ERG, ETV1, and ETV4. Here we report the noninvasive detection of these gene fusions in the urine of patients with clinically localized prostate cancer. By quantitative polymerase chain reaction, we assessed the expression of ERG and TMPRSS2:ERG transcripts in urine samples obtained after prostatic massage from 19 patients (11 prebiopsy and 8 pre-radical prostatectomy) with prostate cancer. We observed a strong concordance between ERG overexpression and TMPRSS2:ERG expression, with 8 of 19 (42%) patients having detectable TMPRSS2:ERG transcripts in their urine. Importantly, by fluorescence in situ hybridization, we confirmed the presence or the absence of TMPRSS2:ERG gene fusions in matched prostate cancer tissue samples from three of three patients with fusion transcripts in their urine and from two of two patients without fusion transcripts in their urine. These results demonstrate that TMPRSS2:ERG gene fusions can be detected in the urine of patients with prostate cancer and support larger studies on prospective cohorts for noninvasive detection of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17059688      PMCID: PMC1715928          DOI: 10.1593/neo.06625

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  12 in total

Review 1.  Chromosome translocations: dangerous liaisons revisited.

Authors:  J D Rowley
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

2.  Vysis UroVysion for the detection of urothelial carcinoma.

Authors:  Kevin C Halling
Journal:  Expert Rev Mol Diagn       Date:  2003-07       Impact factor: 5.225

3.  Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.

Authors:  Maisa Yoshimoto; Anthony M Joshua; Susan Chilton-Macneill; Jane Bayani; Shamini Selvarajah; Andrew J Evans; Maria Zielenska; Jeremy A Squire
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

4.  Whole transcriptome amplification for gene expression profiling and development of molecular archives.

Authors:  Scott A Tomlins; Rohit Mehra; Daniel R Rhodes; Rajal B Shah; Mark A Rubin; Eric Bruening; Vladimir Makarov; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2006-02       Impact factor: 5.715

5.  Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer.

Authors:  Maria Johansson Soller; Margareth Isaksson; Peter Elfving; Wolfgang Soller; Rolf Lundgren; Ioannis Panagopoulos
Journal:  Genes Chromosomes Cancer       Date:  2006-07       Impact factor: 5.006

6.  Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue.

Authors:  K Specht; T Richter; U Müller; A Walch; M Werner; H Höfler
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

7.  Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer.

Authors:  Jianghua Wang; Yi Cai; Chengxi Ren; Michael Ittmann
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

8.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

Authors:  Scott A Tomlins; Rohit Mehra; Daniel R Rhodes; Lisa R Smith; Diane Roulston; Beth E Helgeson; Xuhong Cao; John T Wei; Mark A Rubin; Rajal B Shah; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

Review 9.  Chromosomal translocations in human cancer.

Authors:  T H Rabbitts
Journal:  Nature       Date:  1994-11-10       Impact factor: 49.962

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  85 in total

Review 1.  New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer.

Authors:  Göran Stenman; Mattias K Andersson; Ywonne Andrén
Journal:  Cell Cycle       Date:  2010-08-28       Impact factor: 4.534

2.  Label-free in vitro prostate cancer cell detection via photonic-crystal biosensor.

Authors:  Frank DeLuna; XiaoFei Ding; Ismael Sagredo; Gilbert Bustamante; Lu-Zhe Sun; Jing Yong Ye
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2018-02-20

3.  Telomere attrition in isolated high-grade prostatic intraepithelial neoplasia and surrounding stroma is predictive of prostate cancer.

Authors:  Anthony Michael Joshua; Bisera Vukovic; Ilan Braude; Sundus Hussein; Maria Zielenska; John Srigley; Andrew Evans; Jeremy Andrew Squire
Journal:  Neoplasia       Date:  2007-01       Impact factor: 5.715

Review 4.  TMPRSS2-ETS fusion prostate cancer: biological and clinical implications.

Authors:  Francesca Demichelis; Mark A Rubin
Journal:  J Clin Pathol       Date:  2007-11       Impact factor: 3.411

5.  TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications.

Authors:  Marc Barry; Sven Perner; Francesca Demichelis; Mark A Rubin
Journal:  Urology       Date:  2007-10       Impact factor: 2.649

Review 6.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

7.  Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer.

Authors:  Sooryanarayana Varambally; Bharathi Laxman; Rohit Mehra; Qi Cao; Saravana M Dhanasekaran; Scott A Tomlins; Jill Granger; Adaikkalam Vellaichamy; Arun Sreekumar; Jianjun Yu; Wenjuan Gu; Ronglai Shen; Debashis Ghosh; Lorinda M Wright; Raleigh D Kladney; Rainer Kuefer; Mark A Rubin; Claus J Fimmel; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

8.  [Optimized standards for prostate biopsy].

Authors:  B Wullich; S Füssel; R Grobholz
Journal:  Urologe A       Date:  2007-06       Impact factor: 0.639

Review 9.  Recurrent gene fusions in prostate cancer.

Authors:  Chandan Kumar-Sinha; Scott A Tomlins; Arul M Chinnaiyan
Journal:  Nat Rev Cancer       Date:  2008-06-19       Impact factor: 60.716

10.  ETS gene fusions and prostate cancer.

Authors:  Wei Huang; Michelle Waknitz
Journal:  Am J Transl Res       Date:  2009-05-25       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.